{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-21-020423","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2021-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.096387+00:00","generated_at":"2026-06-29T09:11:20.268808+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"KemPharm appoints Tamara A. Seymour to board and audit committee chair","bullets":["Appointment effective August 18, 2021; Seymour becomes Class I director, term expiring at 2022 annual meeting.","Seymour brings over 30 years life sciences experience, including CFO roles at several public and private biotech firms.","Initial grant of 22,500 stock options vesting in three equal annual installments under 2014 equity plan.","Annual retainers: $35,000 for board service and $22,500 for audit committee chair.","CEO notes appointment comes at 'important phase' as KemPharm seeks organic and external growth opportunities."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-21-020423","json":"https://secwatch.observer/filing/0001437749-21-020423.json","markdown":"https://secwatch.observer/filing/0001437749-21-020423.md","text":"https://secwatch.observer/filing/0001437749-21-020423.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774921020423/0001437749-21-020423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774921020423/kmph20210817_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T09:11:20.268808+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"480ef8cbe5","claim":"Tamara A. Seymour was appointed as Director and Chair of the Audit Committee at ZEVRA THERAPEUTICS, INC..","evidence_excerpt":"the board of directors (the “Board”) of KemPharm, Inc. (the “Company”) appointed Tamara A. Seymour to serve as a director of the Company and as the chair of the Company’s audit committee.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774921020423/0001437749-21-020423-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director and Chair of the Audit Committee"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}